Data Supplement from Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Year: 2023
Type: other
Abstract: Supplementary Figures S1-S8. Levels of RAS-GTP in melanoma cell lines (S1); Changes in pERK and cyclin D1 levels as function of time in cells treated with the MEK inhibitor PD0325901 (S2); Sk-Mel-113 (NF1 null) melanoma cells are resistant to AKT inhibition (S3); Variability in induction of pMEK levels following exposure to four allosteric MEK inhibitors (S4); Exon-capture deep sequencing via IMPACT of the NF1 gene in M308 shows a nonsense Q1070* mutation (S5); Expression of activated RAS is sufficient to confer resistance to vemurafenib in Sk-Mel-239 (BRAF V600E) cells (S6); Sensitivity of A375 (BRAF V600E) cells to vemurafenib (S7); The MAPK pathway and the inhibitors used in the study of NF1-null cells (S8).
Authors: Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo Ramirez, Helen Won, Cailian Liu, Shakuntala Tiwari, Li Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub, Antoni Ribas, Paul B. Chapman, Rona Yaeger, Barry S. Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361864720